Pharmaceutical | Page 12 of 46

Diabetes :: Diabetes professionals join forces to identify gaps in diabetes care and better self care

A symposium, sponsored by the American Journal of Nursing (AJN) in collaboration with the American Diabetes Association, the American Association of Diabetes Educators, Joslin Diabetes Center and the University of Pennsylvania School of Nursing identified barriers to, and strategies for, more effective diabetes self management and reaffirmed the nurse’s critical role to facilitate better patient self care. These results are published in a special supplement to the June issue of AJN.

Gene :: UVa-led team uncovers important secret in gene replication

A team of researchers led by University of Virginia Health System geneticists has uncovered a major secret in the mystery of how the DNA helix replicates itself time after time. It turns out that it is not just the sequence of the bases — building blocks — in the DNA, but also how loosely or tightly the chromatin — the material that makes up chromosomes — is packed at different points of the chromosome that is critical.

Dialysis :: As dialysis becomes a target of cost control, doctor-patient relationship is key

As medical, economic, and policy trends converge to alter the way dialysis care is organized and financed, protecting the unique relationship between dialysis patients and the kidney specialists who direct their care is a top priority, according to a special feature in the July Journal of the American Society of Nephrology.

Drug :: Could fungal collection hold the key to new life-saving drugs?

Scientists may be one step closer to finding new drugs to fight MRSA, cancers and other diseases, after CABI, a leading bioservices organisation announced that its fungal collection will be screened by the University of Strathclyde.

Autism :: Researchers reveal structure of protein altered in autism

As a result of mapping the structure of the protein complex implicated in autism spectrum disorders, a research team led by scientists at the University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences has discovered how particular genetic mutations affect this complex and contribute to the developmental abnormalities found in children with autism.

Autism :: Vaccine-induced autism victims in the thousands will finally get day in court

Hearings will begin on June 11th at the U.S. Federal Claims Court to determine if autism is linked to vaccines and their components, including the mercury-based preservative thimerosal. As the Autism Omnibus Proceeding approaches, parents of children diagnosed with autism are calling attention to the conflicts of interest they believe continue to threaten the safety of vaccines.

Autism :: Vaccine-induced autism hearings to present science supporting parents’ claims

Hearings are scheduled to begin in the U.S Federal Claims Court where over 4,800 parents have filed for compensation for their children who developed autism after exposure to infant vaccines. A majority of those claims revolve around the use of thimerosal, a mercury-containing preservative.

Alzheimer’s Disease :: Early Results from Alzheimer’s Neuroimaging Biomarker Project

Alzheimer’s disease researchers may be able to reduce the time and expense associated with clinical trials, according to early results from the Alzheimer?s Disease Neuroimaging Initiative (ADNI), a public-private research partnership organized by the National Institutes of Health. Preliminary results from ADNI show how it might yield improved methods and uniform standards for imaging and biomarker analysis, so these techniques can be employed in the fight against Alzheimer?s disease.

Antibiotic :: New drug application submitted for investigational antibiotic Doripenem

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for doripenem, an investigational carbapenem antibiotic for the treatment of nosocomial pneumonia, a pneumonia that is acquired in a hospital or other healthcare setting.

Multiple Sclerosis :: Teva & Active Biotech to initiate trial of oral laquinimod for relapsing multiple sclerosis

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech AB (OMX NORDIC: ACTI) announced that the companies are initiating a clinical Phase III program for laquinimod, a novel once-daily, orally administered immunomodulatory compound for the treatment of relapsing multiple sclerosis (RMS).